38 related articles for article (PubMed ID: 10472357)
1. Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)-Hyaluronan Complex in Endometrial Cancer.
Yabushita H; Iwasaki K; Kanyama K; Obayashi Y; Zhuo L; Itano N; Kimata K; Wakatsuki A
Obstet Gynecol Int; 2011; 2011():739150. PubMed ID: 21904555
[TBL] [Abstract][Full Text] [Related]
2. Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.
Honkavuori-Toivola M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
Dis Markers; 2013; 35(4):261-6. PubMed ID: 24344400
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.
Honkavuori-Toivola M; Talvensaari-Mattila A; Soini Y; Turpeenniemi-Hujanen T; Santala M
Tumour Biol; 2012 Aug; 33(4):935-41. PubMed ID: 22270451
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance.
Yilmaz E; Koyuncuoglu M; Görken IB; Okyay E; Saatli B; Ulukus EC; Saygili U
J Gynecol Oncol; 2011 Jun; 22(2):89-96. PubMed ID: 21860734
[TBL] [Abstract][Full Text] [Related]
5. Relationship between matrix metalloproteinase 2 and lung cancer progression.
Guo CB; Wang S; Deng C; Zhang DL; Wang FL; Jin XQ
Mol Diagn Ther; 2007; 11(3):183-92. PubMed ID: 17570740
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma.
Korpi JT; Hagström J; Lehtonen N; Parkkinen J; Sorsa T; Salo T; Laitinen M
Surg Oncol; 2011 Mar; 20(1):e18-22. PubMed ID: 20880700
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer.
Moser PL; Kieback DG; Hefler L; Tempfer C; Neunteufel W; Gitsch G
Anticancer Res; 1999; 19(5C):4391-3. PubMed ID: 10650781
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
9. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
Guo W; Chen G; Zhu C; Wang H
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
[TBL] [Abstract][Full Text] [Related]
10. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.
Grignon DJ; Sakr W; Toth M; Ravery V; Angulo J; Shamsa F; Pontes JE; Crissman JC; Fridman R
Cancer Res; 1996 Apr; 56(7):1654-9. PubMed ID: 8603416
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and metastatic cancer.
Cockett MI; Murphy G; Birch ML; O'Connell JP; Crabbe T; Millican AT; Hart IR; Docherty AJ
Biochem Soc Symp; 1998; 63():295-313. PubMed ID: 9513731
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
